Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107159 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00107159 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 37 participants.
The verdict
NCT00107159, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's white blood cells and a donor's tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with unresected stage III or stage IV melanoma.
Interventions
- BIOLOGICAL autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2005-01 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107159
The ClinicalTrials.gov registry entry for NCT00107159 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine is the first listed.
NCT00107159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00107159 about?
NCT00107159 is a clinical study titled "Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma". RATIONALE: Vaccines made from a person's white blood cells and a donor's tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with unresected stage III or stage IV melanoma.
What is the current status of trial NCT00107159?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2005-01. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00107159?
The interventions under investigation include: autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00107159?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.